Actively Recruiting
Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50
Led by University Hospital, Strasbourg, France · Updated on 2026-01-02
830
Participants Needed
1
Research Sites
51 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.
CONDITIONS
Official Title
Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with relapsing-remitting multiple sclerosis (RRMS) onset after age 50
- Patients who started their first disease-modifying therapy within 2 years of the first symptoms
- Patients treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) such as teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, or peginterferon
- Patients treated with highly effective DMARDs such as fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, or cladribine
You will not qualify if you...
- Patients with early progressive multiple sclerosis (MS)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre d'Investigation Clinique - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
N
Nicolas Collongues, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here